HK Stock Market Move | XUANZHUBIO-B (02575) surged over 40% in the afternoon, with its revenue in the first half of the year skyrocketing nearly threefold year-on-year. This year marks the full-scale launch year for Xuan Yuening.

XUANZHUBIO-B (02575) soared over 40% in the afternoon. As of the time of reporting, it was up 38.22% at HKD 13.0, with a trading volume of HKD 43.6583 million. In terms of news, Xuan Zhu Bio achieved revenue of RMB 69.4 million in the first half of the year, a year-on-year increase of 288.1%, mainly driven by the launch of new products and inclusion in the national essential medicines list. It is reported that Xuan Yue Ning has added a first-line indication and been included in the medical insurance list in March 2026, marking 2026 as its first full-scale launch year. Xuan Fei Ning, with a high intracranial objective response rate of 91.7% and a low discontinuation rate of 1.5%, directly faces competition from third-generation drugs in the ALK-positive NSCLC field, showing clear differentiation advantages. Northeast previously released a research report stating that the company has constructed a full-chain platform for small molecules, large molecules, and small nucleic acids. The core asset under research, XZP-7797, has initiated Phase I clinical trials, with data expected in Q4 2026. Based on transactions of similar assets, it has a high potential for overseas licensing. The company's business development strategy is pragmatic, and in April 2026, it reached licensing agreements with Boston Oncology for 21 countries in the Middle East and North Africa, with potential milestones exceeding USD 100 million, validating its international monetization capability. In the future, it does not rule out reaching larger-scale transactions for early pipelines in mainstream markets in Europe and the United States.